Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

XLV vs VGHCX overlap: 53% of top holdings shared

Bottom line

How much do XLV and VGHCX overlap?

53% of their top holdings overlap by weight. 14 securities appear in both funds' top 25, making up 61.7% of XLV's assets and 44.5% of VGHCX's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

XLVVGHCX
Weight overlap (top 25)53%
Shared holdings14
Weight in shared holdings61.7%44.5%
Total positions6597
Expense ratio0.08%0.33%
Holdings as ofJun 30, 2026Jul 31, 2026

Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)

Holdings XLV and VGHCX have in common

Holding% of XLV% of VGHCXOverlap
Eli Lilly & Co16.51%8.61%8.61%
Johnson & Johnson10.64%4.83%4.83%
AbbVie Inc7.74%2.30%2.30%
UnitedHealth Group Inc6.57%4.05%4.05%
Merck & Co Inc5.52%5.44%5.44%
Intuitive Surgical Inc2.45%2.52%2.45%
CVS Health Corp2.30%2.52%2.30%
Vertex Pharmaceuticals Inc2.19%2.36%2.19%
Danaher Corp2.09%2.18%2.09%
Elevance Health Inc1.46%1.83%1.46%
Boston Scientific Corp1.10%1.53%1.10%
Regeneron Pharmaceuticals Inc1.08%2.14%1.08%
HCA Healthcare Inc1.05%1.68%1.05%
Cencora Inc0.96%2.47%0.96%

Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in XLV

  1. Amgen Inc — 3.40%
  2. Thermo Fisher Scientific Inc — 3.24%
  3. Abbott Laboratories — 2.75%
  4. Gilead Sciences Inc — 2.73%
  5. Pfizer Inc — 2.39%
  6. Bristol-Myers Squibb Co — 2.05%
  7. Stryker Corp — 1.89%
  8. Medtronic PLC — 1.75%
  9. McKesson Corp — 1.58%
  10. Cigna Group/The — 1.27%
  11. Cardinal Health Inc — 0.97%

Only in VGHCX

  1. AstraZeneca PLC — 4.59%
  2. Gsk Plc — 3.00%
  3. Edwards Lifesciences Corp — 2.56%
  4. Novartis AG — 1.91%
  5. Argenx SE — 1.68%
  6. Ucb Sa — 1.67%
  7. Agilent Technologies Inc — 1.49%
  8. Biogen Inc — 1.46%
  9. Galderma Group AG — 1.37%
  10. Roche Holding AG — 1.18%
  11. Dexcom Inc — 1.18%

Asset mix

Asset typeXLVVGHCX
Stocks99.7%97.6%
Repurchase agreements—2.2%
Cash & short-term funds0.3%0.1%

Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)

Country mix

CountryXLVVGHCX
US97.9%77.6%
GB—7.6%
JP—4.8%
CH—4.5%
BE—3.4%
IE2.1%—
DK—1.4%
HK—0.8%

Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)

Check another pair

FAQ

How much do XLV and VGHCX overlap?
About 53% by weight. 14 securities appear in both funds' top 25 holdings; they make up 61.7% of XLV's assets and 44.5% of VGHCX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do XLV and VGHCX have in common?
The largest shared holdings are Eli Lilly & Co, Merck & Co Inc, Johnson & Johnson, UnitedHealth Group Inc, Intuitive Surgical Inc.
Should I own both XLV and VGHCX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, XLV or VGHCX?
VGHCX is broader, with 97 positions versus 65 for XLV. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.